These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 12875709)

  • 21. Regression of liver fibrosis in hepatitis C virus/HIV-co-infected patients after treatment with pegylated interferon plus ribavirin.
    Soriano V; Labarga P; Ruiz-Sancho A; Garcia-Samaniego J; Barreiro P
    AIDS; 2006 Nov; 20(17):2225-7. PubMed ID: 17086063
    [No Abstract]   [Full Text] [Related]  

  • 22. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C.
    Yu ML; Dai CY; Huang JF; Hou NJ; Lee LP; Hsieh MY; Chiu CF; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL
    Gut; 2007 Apr; 56(4):553-9. PubMed ID: 16956917
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Do the interferons have an antifibrotic action? The hepatologist's point of view].
    Poynard T
    Rev Med Interne; 2002 Nov; 23 Suppl 4():517s-521s. PubMed ID: 12481408
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Experiences in antiviral treatment of chronic viral hepatitis B and C in Hungary (1998-2004)].
    Pár A; Tornai I; Szalay F
    Orv Hetil; 2007 May; 148(18):819-26. PubMed ID: 17468063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Interferons alpha in the treatment of chronic HCV infections].
    Halota W; Pawłowska M; Andrejczyn M
    Przegl Epidemiol; 2004; 58(3):405-11. PubMed ID: 15730004
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pegylated interferon: new preparation. Chronic hepatitis C: advantageous for some patients, but more data needed.
    Prescrire Int; 2003 Dec; 12(68):206-10. PubMed ID: 14986684
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A study of low dose peginterferon alpha-2b with ribavirin for the initial treatment of chronic hepatitis C.
    Krawitt EL; Gordon SR; Grace ND; Ashikaga T; Ray MA; Palmer M; Yarze JC; Moskowitz S;
    Am J Gastroenterol; 2006 Jun; 101(6):1268-73. PubMed ID: 16771948
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peginterferon and ribavirin for hepatitis C.
    Leiner S
    N Engl J Med; 2007 Mar; 356(12):1270; author reply 1271. PubMed ID: 17380577
    [No Abstract]   [Full Text] [Related]  

  • 29. [High dose of pegylated interferon alpha-2a for the treatment of genotype1 chronic hepatitis C: a case report].
    Wu CH; Wang LF; Xu XY
    Zhonghua Gan Zang Bing Za Zhi; 2010 Nov; 18(11):873. PubMed ID: 21138646
    [No Abstract]   [Full Text] [Related]  

  • 30. [Protocol for the antiviral therapy of chronic hepatitis C].
    ; ; Gervain J; Horváth G; Hunyady B; Makara M; Pár A; Szalay F; Tornai I; Telegdy L
    Orv Hetil; 2008 Dec; 149(52):2479-83. PubMed ID: 19087916
    [No Abstract]   [Full Text] [Related]  

  • 31. Safety and efficacy of treatment for chronic hepatitis C with a focus on pegylated interferons: the backbone of therapy today and in the future.
    Ferenci P
    Expert Opin Drug Saf; 2011 Jul; 10(4):529-44. PubMed ID: 21345149
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Review article: pegylated interferons: chemical and clinical differences.
    Foster GR
    Aliment Pharmacol Ther; 2004 Oct; 20(8):825-30. PubMed ID: 15479353
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reversal of cirrhosis: evidence-based medicine?
    Desmet VJ; Roskams T
    Gastroenterology; 2003 Aug; 125(2):629-30; author reply 630-31. PubMed ID: 12891578
    [No Abstract]   [Full Text] [Related]  

  • 34. [Due to normal transaminase values, no further treatment. Hepatitis C patient "suddenly" has liver cirrhosis].
    MMW Fortschr Med; 2004 May; 146(19):64. PubMed ID: 15357490
    [No Abstract]   [Full Text] [Related]  

  • 35. Induction therapy in chronic hepatitis C: déjà-vu with pegylated interferons?
    Zeuzem S
    J Hepatol; 2004 Sep; 41(3):488-90. PubMed ID: 15336454
    [No Abstract]   [Full Text] [Related]  

  • 36. Treatment of cirrhotic patients in the pegylated interferon era.
    Poynard T
    Dig Liver Dis; 2004 Nov; 36 Suppl 3():S344-8. PubMed ID: 15645665
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment of chronic hepatitis C with peginterferon alpha-2a and the factors influencing the effect of this treatment].
    Jin GD; Gong QM; Mao HJ; Xu DZ; Lu ZM
    Zhonghua Gan Zang Bing Za Zhi; 2005 Apr; 13(4):302-4. PubMed ID: 15850524
    [No Abstract]   [Full Text] [Related]  

  • 38. Clinical management of a patient with drug dependence who attempted suicide while receiving peginterferon therapy for chronic hepatitis C.
    Fábregas BC; Moura AS; Marciano RC; Carmo RA; Teixeira AL
    Braz J Infect Dis; 2009 Oct; 13(5):387-90. PubMed ID: 20428642
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Development of antiviral therapy for patients with chronic hepatitis C].
    Hayashi N; Oze T; Hiramatsu N
    Nihon Shokakibyo Gakkai Zasshi; 2008 Feb; 105(2):175-85. PubMed ID: 18250587
    [No Abstract]   [Full Text] [Related]  

  • 40. [Interferon in the treatment of viral hepatitis. The interferon was discovered 50 years ago].
    Fehér J; Lengyel G
    Orv Hetil; 2007 Aug; 148(33):1539-43. PubMed ID: 17686671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.